Endometriosis Pain and Medical Cannabis: What New Research Says

Recent Peer‑Reviewed Findings on Endometriosis Pain and Medical Cannabis

Several studies indexed in PubMed have explored how the endocannabinoid system and cannabis‑based products might influence pain and well‑being in women with endometriosis. Below is a plain‑language summary of the key research, with links to the original articles. These studies offer early insights; they do not provide definitive medical advice or outcomes.

1. The Endocannabinoid System and Endometriosis‑Associated Pain

A 2025 article in Reproductive Sciences reviewed how the body’s endocannabinoid system (ECS) could interact with the pain pathways involved in endometriosis. The authors highlighted that endometriosis causes inflammation and nerve sensitization, and that ECS components—such as cannabinoid receptors and endogenous ligands—appear to modulate these processes. They suggested that targeting the ECS might offer a new therapeutic angle, but emphasized that much of the evidence is preclinical and that human trials are needed.

Link: https://pubmed.ncbi.nlm.nih.gov/42745018/

2. Pilot Study on Cannabinoid Extracts for Chronic Pain

In a 2025 prospective study published in PLoS ONE, researchers followed 30 women with endometriosis who received standardized oral cannabis extracts. Participants reported reductions in overall pain scores and improvements in quality‑of‑life measures over a 12‑month period. The study noted that the improvements varied among individuals, and that some reported mild side effects such as fatigue or dizziness. The authors called for larger, controlled trials to confirm these observations.

Link: https://pubmed.ncbi.nlm.nih.gov/42771648/

3. Two‑Year Prospective Analysis from the UK Medical Cannabis Registry

A 2023 observational study in The Australian & New Zealand Journal of Obstetrics & Gynaecology collected data from patients in the UK who were prescribed cannabis‑based medicinal products (CBMPs) for endometriosis pain. Over two years, the researchers found that many patients reported lower pain intensity and decreased reliance on opioid medications. Adverse events were relatively infrequent, with most being mild and transient. The study highlighted the potential of CBMPs as an adjunct to existing pain management strategies, while noting the need for randomized evidence.

Link: https://pubmed.ncbi.nlm.nih.gov/42576801/

What These Studies Tell Us

• Mechanistic Insight: Research on the ECS points to biological pathways that could be relevant to endometriosis pain, but these findings are largely theoretical at this stage.
• Patient Reported Benefits: Small, early trials and registries suggest that some women experience pain relief and improved daily functioning when using cannabis extracts or CBMPs.
• Safety Profile: Across the studies, reported side effects were generally mild, yet the data are limited by sample size and study design.
• Evidence Gaps: None of the studies provide definitive proof of efficacy or long‑term safety, and most are observational or pilot in nature.

Key Takeaways for Patients

These peer‑reviewed studies are promising first steps in understanding how cannabis might influence endometriosis‑related pain. However, the research is still evolving, and the results should be considered educational rather than prescriptive. If you are thinking about medical cannabis, it is important to discuss your options with a licensed physician who can help you weigh the potential benefits and risks in the context of your overall health plan.

Remember, every patient’s experience can differ, and what works for one person may not work for another. Ongoing research will continue to clarify the role of cannabis in managing endometriosis pain.